State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures
Since the Hedgehog signaling pathway has been associated with cancer, it has emerged as a therapeutic target for cancer therapy. The main target among the key Hedgehog proteins is the GPCR-like Smo receptor. Therefore, some Smo antagonists that have entered clinical trials, including the US FDA-approved drugs vismodegib and sonidegib, to treat basal cell carcinoma and medulloblastoma. However, early resistance of these drugs has spawned the need to understand the molecular bases of this phenomena. We therefore reviewed details about Smo receptor structures and the best Smo antagonist chemical structures. In addition, we discussed strategies that should be considered to develop new, safer generations of Smo antagonists that avoid current clinical limitations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 11(2019), 6, Seite 617- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Espinosa-Bustos, Christian [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (22 p) |
|---|
| doi: |
10.4155/fmc-2018-0497 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL001069780 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL001069780 | ||
| 003 | DE-627 | ||
| 005 | 20230430081615.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210608s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2018-0497 |2 doi | |
| 035 | |a (DE-627)KFL001069780 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/fmc-2018-0497 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Espinosa-Bustos, Christian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (22 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Since the Hedgehog signaling pathway has been associated with cancer, it has emerged as a therapeutic target for cancer therapy. The main target among the key Hedgehog proteins is the GPCR-like Smo receptor. Therefore, some Smo antagonists that have entered clinical trials, including the US FDA-approved drugs vismodegib and sonidegib, to treat basal cell carcinoma and medulloblastoma. However, early resistance of these drugs has spawned the need to understand the molecular bases of this phenomena. We therefore reviewed details about Smo receptor structures and the best Smo antagonist chemical structures. In addition, we discussed strategies that should be considered to develop new, safer generations of Smo antagonists that avoid current clinical limitations | ||
| 700 | 1 | |a Mella, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Soto-Delgado, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Salas, Cristian O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d London : Future Science, 2009 |g 11(2019), 6, Seite 617- |h Online-Ressource |w (DE-627)KFL000006157 |w (DE-600)2572258-X |w (DE-576)398101442 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:6 |g pages:617- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/fmc-2018-0497 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 6 |h 617- | ||